Comments
Loading...

Cara Therapeutics Analyst Ratings

CARANASDAQ
Logo brought to you by Benzinga Data
$5.58
0.183.33%
Pre-Market: 4:54 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$28.00
Lowest Price Target1
$1.00
Consensus Price Target1
$11.33

Cara Therapeutics Analyst Ratings and Price Targets | NASDAQ:CARA | Benzinga

Cara Therapeutics Inc has a consensus price target of $11.33 based on the ratings of 8 analysts. The high is $28 issued by Stifel on June 27, 2023. The low is $1 issued by Canaccord Genuity on June 13, 2024. The 3 most-recent analyst ratings were released by Canaccord Genuity, Needham, and HC Wainwright & Co. on June 13, 2024, May 23, 2024, and May 15, 2024, respectively. With an average price target of $3.2 between Canaccord Genuity, Needham, and HC Wainwright & Co., there's an implied -42.65% downside for Cara Therapeutics Inc from these most-recent analyst ratings.

Analyst Rating and Forecast
12345
3.1
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Canaccord Genuity
Piper Sandler
Stifel
Jefferies
B of A Securities

1calculated from analyst ratings

Analyst Ratings for Cara Therapeutics

Buy NowGet Alert
06/13/2024Buy Now-82.08%Canaccord Genuity
Sumant Kulkarni44%
$120 → $12DowngradeBuy → HoldGet Alert
06/13/2024Buy NowHC Wainwright & Co.
Oren Livnat61%
DowngradeBuy → NeutralGet Alert
06/13/2024Buy NowNeedham
Joseph Stringer52%
DowngradeBuy → HoldGet Alert
05/23/2024Buy Now-10.39%Needham
Joseph Stringer52%
$60 → $60ReiteratesBuy → BuyGet Alert
05/15/2024Buy Now-35.48%HC Wainwright & Co.
Oren Livnat61%
$43.2 → $43.2ReiteratesBuy → BuyGet Alert
05/14/2024Buy Now-10.39%Needham
Joseph Stringer52%
$60 → $60ReiteratesBuy → BuyGet Alert
04/10/2024Buy Now-10.39%Needham
Joseph Stringer52%
$60 → $60ReiteratesBuy → BuyGet Alert
03/28/2024Buy Now-10.39%Needham
Joseph Stringer52%
$60 → $60ReiteratesBuy → BuyGet Alert
03/06/2024Buy Now79.21%Canaccord Genuity
Sumant Kulkarni44%
$132 → $120MaintainsBuyGet Alert
03/05/2024Buy Now-10.39%Needham
Joseph Stringer52%
$60 → $60ReiteratesBuy → BuyGet Alert
01/22/2024Buy Now-10.39%Needham
Joseph Stringer52%
$72 → $60MaintainsBuyGet Alert
12/19/2023Buy Now-55.2%HC Wainwright & Co.
Oren Livnat61%
$84 → $30MaintainsBuyGet Alert
12/18/2023Buy Now7.53%Needham
Joseph Stringer52%
$264 → $72MaintainsBuyGet Alert
11/14/2023Buy Now-82.08%Piper Sandler
David Amsellem70%
$144 → $12DowngradeOverweight → NeutralGet Alert
10/19/2023Buy Now25.45%HC Wainwright & Co.
Oren Livnat61%
$180 → $84MaintainsBuyGet Alert
08/08/2023Buy Now115.06%Piper Sandler
David Amsellem70%
$156 → $144MaintainsOverweightGet Alert
08/08/2023Buy Now294.27%Needham
Joseph Stringer52%
→ $264ReiteratesBuy → BuyGet Alert
06/27/2023Buy Now401.8%Stifel
Annabel Samimy68%
→ $336ReiteratesBuy → BuyGet Alert
06/27/2023Buy Now222.59%Jefferies
Dennis Ding16%
→ $216ReiteratesBuy → BuyGet Alert
05/16/2023Buy Now168.82%HC Wainwright & Co.
Oren Livnat61%
$240 → $180MaintainsBuyGet Alert
05/16/2023Buy Now-28.31%B of A Securities
Jason Gerberry63%
$72 → $48MaintainsUnderperformGet Alert
05/16/2023Buy Now294.27%Needham
Joseph Stringer52%
→ $264Reiterates → BuyGet Alert
04/18/2023Buy Now294.27%Needham
Joseph Stringer52%
→ $264Reiterates → Action List BuyGet Alert
04/04/2023Buy Now294.27%Needham
Joseph Stringer52%
→ $264Reiterates → BuyGet Alert
03/08/2023Buy Now7.53%B of A Securities
Jason Gerberry63%
$156 → $72DowngradeNeutral → UnderperformGet Alert
03/07/2023Buy Now186.74%JP Morgan
Daniel Wolle9%
$228 → $192MaintainsOverweightGet Alert
03/07/2023Buy Now348.04%Canaccord Genuity
Sumant Kulkarni44%
$348 → $300MaintainsBuyGet Alert
03/07/2023Buy Now294.27%Needham
Joseph Stringer52%
$312 → $264MaintainsBuyGet Alert
03/07/2023Buy Now132.98%Piper Sandler
David Amsellem70%
$300 → $156MaintainsOverweightGet Alert
03/07/2023Buy Now258.43%HC Wainwright & Co.
Oren Livnat61%
$300 → $240MaintainsBuyGet Alert
02/17/2023Buy Now365.96%Needham
Joseph Stringer52%
→ $312Reiterates → BuyGet Alert
02/14/2023Buy Now348.04%HC Wainwright & Co.
Oren Livnat61%
$360 → $300MaintainsBuyGet Alert

FAQ

Q

What is the target price for Cara Therapeutics (CARA) stock?

A

The latest price target for Cara Therapeutics (NASDAQ:CARA) was reported by Canaccord Genuity on June 13, 2024. The analyst firm set a price target for $1.00 expecting CARA to fall to within 12 months (a possible -82.08% downside). 8 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Cara Therapeutics (CARA)?

A

The latest analyst rating for Cara Therapeutics (NASDAQ:CARA) was provided by Canaccord Genuity, and Cara Therapeutics downgraded their hold rating.

Q

When was the last upgrade for Cara Therapeutics (CARA)?

A

There is no last upgrade for Cara Therapeutics

Q

When was the last downgrade for Cara Therapeutics (CARA)?

A

The last downgrade for Cara Therapeutics Inc happened on June 13, 2024 when Canaccord Genuity changed their price target from $10 to $1 for Cara Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Cara Therapeutics (CARA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cara Therapeutics was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.

Q

Is the Analyst Rating Cara Therapeutics (CARA) correct?

A

While ratings are subjective and will change, the latest Cara Therapeutics (CARA) rating was a downgraded with a price target of $10.00 to $1.00. The current price Cara Therapeutics (CARA) is trading at is $5.58, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.